LB Pharmaceuticals Inc Common Stock
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 1 clinical trial for the treatment of bipolar I depression; and in … Read more
LB Pharmaceuticals Inc Common Stock (LBRX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.011x
Based on the latest financial reports, LB Pharmaceuticals Inc Common Stock (LBRX) has a cash flow conversion efficiency ratio of -0.011x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.37 Million) by net assets ($310.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
LB Pharmaceuticals Inc Common Stock - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how LB Pharmaceuticals Inc Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
LB Pharmaceuticals Inc Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LB Pharmaceuticals Inc Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nelson Select ETF
BATS:NELS
|
N/A |
|
SDX ENERGY PLCLS 001
F:3KX
|
N/A |
|
Morgan Group Holding Co
PINK:MGHL
|
0.104x |
|
Osprey Bitcoin Trust
OTCQX:OBTC
|
N/A |
|
NeutriSci International Inc
PINK:NRXCF
|
0.006x |
|
PFA Invest Globale Aktier Fund
CO:PFIGLA
|
N/A |
|
Carlyle Secured Lending Inc. 8.20% Notes due 2028
NASDAQ:CGBDL
|
N/A |
|
MGO Global Inc. Common Stock
NASDAQ:MGOL
|
-0.567x |
Annual Cash Flow Conversion Efficiency for LB Pharmaceuticals Inc Common Stock (2022–2024)
The table below shows the annual cash flow conversion efficiency of LB Pharmaceuticals Inc Common Stock from 2022 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-94.55 Million | $-53.05 Million | 0.561x | +59.93% |
| 2023-12-31 | $-34.47 Million | $-12.09 Million | 0.351x | +270.53% |
| 2022-12-31 | $-28.81 Million | $-2.73 Million | 0.095x | -- |